ESPR (Esperion Therapeutics) Institutional Ownership: 68.19% (As of Aug. 04, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ESPR Esperion Therapeutics Inc ESPR
62 GF Score
Price $3.18
GF Value $2.30
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Esperion Therapeutics Institutional Ownership?

Esperion Therapeutics ESPR -0.31% 62 Institutional Ownership is 68.19% as of Aug. 04, 2026. GuruFocus rates ESPR with a GF Score™ of 62/100 and a GF Value™ of $2.30 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Esperion Therapeutics's institutional ownership is 68.19%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Esperion Therapeutics's Insider Ownership is 2.67%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Esperion Therapeutics's Float Percentage Of Total Shares Outstanding is 98.28%.

Esperion Therapeutics Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Esperion Therapeutics's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Esperion Therapeutics Institutional Ownership Chart

Esperion Therapeutics Historical Data

The historical data trend for Esperion Therapeutics can be seen below:

2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 31.26 26.84 27.38 30.40 30.44 30.62 32.33 31.07 30.09 31.95
ESPR
62GF Score
Esperion Therapeutics Inc ESPR
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Esperion Therapeutics Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 68.19% mean?
Esperion Therapeutics (ESPR) has a Institutional Ownership of 68.19% as of Aug. 04, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Esperion Therapeutics and its competitors.
Is Esperion Therapeutics' Institutional Ownership too high?
Esperion Therapeutics' current Institutional Ownership is 68.19%. Overall, Esperion Therapeutics has a GF Score™ of 62/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Esperion Therapeutics' Institutional Ownership compare to AMPH and NIKA?
Esperion Therapeutics' Institutional Ownership of 68.19% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Drug Manufacturers company?
A good Institutional Ownership depends on the Drug Manufacturers industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Esperion Therapeutics and its competitors. Esperion Therapeutics's current Institutional Ownership is 68.19%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Esperion Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Esperion Therapeutics (ESPR) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.30, compared to a current price of $3.18 — trading 38.3% above its estimated fair value. The current Institutional Ownership is 68.19%. Esperion Therapeutics' overall GF Score™ is 62/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Esperion Therapeutics (ESPR), the current Institutional Ownership is 68.19% as of Aug. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Esperion Therapeutics (ESPR) Overvalued in 2026?

Based on GuruFocus' analysis, Esperion Therapeutics stock appears to be overvalued. The current stock price of $3.18 is trading 38.3% above its estimated GF Value™ of $2.30. GuruFocus considers Esperion Therapeutics to be Significantly Overvalued.

Key valuation signals for ESPR:

  • Institutional Ownership: 68.19%
  • GF Value™: $2.30 vs. price of $3.18 (38.3% above fair value)
  • GF Score™: 62/100 with 6 warning signs

No single metric tells the full story. See the ESPR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Esperion Therapeutics Business Description

Other Exchanges 0IIM:UK0ET:Germany
Address 3891 Ranchero Drive, Suite 150, Ann Arbor, MI, USA, 48108
Esperion Therapeutics Inc is a commercial-stage biopharmaceutical company currently focused on bringing new medicines to patients that address unmet medical needs. It has developed and is commercializing U.S. Food and Drug Administration, or FDA, approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (or CVD and are struggling with elevated low-density lipoprotein cholesterol, or LDL-C. The Company views its operations and manages its business in one operating segment, which is the business of researching, developing, and commercializing therapies for the treatment of patients with elevated LDL-C. The company depends almost entirely on the success of two products, the bempedoic acid tablet and the bempedoic acid/ezetimibe combination tablet.
62GF Score

Get the complete analysis for ESPR

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.18
Price
$2.30
GF Value